| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3391216 | Seminarios de la Fundación Española de Reumatología | 2009 | 5 Pages |
Abstract
In conclusion, the TOPAS and OSPAL clinical trials indicate that LFN is an efficacious and first-line therapeutic option for the treatment of PsA, providing therapeutic benefits for rheumatic symptoms and positive effects on dactylitis and cutaneous symptoms.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Ingrid Möller,